The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA
- PMID: 22129077
- PMCID: PMC3334645
- DOI: 10.1186/ar3524
The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA
Abstract
Introduction: The antigen recognition pattern of immunoglobulin M (IgM) could, when directed against protein antigens, provide an indication of the antigenic moieties triggering new B cells. The half-life of IgM is short and memory B cells against T-cell-dependent protein antigens typically produce IgG and not IgM antibodies. In this study, we analyzed whether a difference exists between the fine specificity of IgM versus IgG anti-citrullinated protein antibodies (ACPAs).
Methods: We determined the fine specificity of IgM and IgG ACPAs in 113 ACPA-positive rheumatoid arthritis patients with IgM cyclic citrullinated peptide 2 (CCP2) levels above 100 AU/ml. Fine specificity was assessed by performing ELISA using citrullinated peptides derived from vimentin, fibrinogen-β, fibrinogen-α and α-enolase, as well as citrullinated proteins fibrinogen and myelin basic protein. The arginine counterparts were used as controls.
Results: Recognition of defined citrullinated antigens by IgM ACPA was confined to samples that also displayed recognition by IgG ACPA. However, the IgM ACPA response displayed a more restricted antigen recognition profile than IgG ACPA (OR = 0.26, P < 0.0001).
Conclusion: Our data show that several defined citrullinated antigens are recognized only by IgG ACPA, whereas others are also recognized by IgM ACPA. These observations suggest that not all citrullinated antigens are able to activate new B cells despite concurrent recognition by IgG ACPA.
Figures



Similar articles
-
Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint.Arthritis Res Ther. 2014 Aug 12;16(4):R167. doi: 10.1186/ar4683. Arthritis Res Ther. 2014. PMID: 25112157 Free PMC article.
-
IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Anti-Citrullinated Protein Antibody-Associated or Isotype-Switched IgA Responses.Arthritis Rheumatol. 2015 Dec;67(12):3124-34. doi: 10.1002/art.39299. Arthritis Rheumatol. 2015. PMID: 26246004
-
Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.Clin Exp Rheumatol. 2014 Sep-Oct;32(5):622-9. Epub 2014 Sep 5. Clin Exp Rheumatol. 2014. PMID: 25189876
-
Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.Rheumatol Int. 2016 Jun;36(6):781-91. doi: 10.1007/s00296-016-3472-9. Epub 2016 Apr 2. Rheumatol Int. 2016. PMID: 27038800 Free PMC article.
-
The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis.Rheumatology (Oxford). 2011 May;50(5):830-7. doi: 10.1093/rheumatology/keq419. Epub 2011 Jan 27. Rheumatology (Oxford). 2011. PMID: 21278075 Free PMC article. Review.
Cited by
-
The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis.Arthritis Res Ther. 2016 Jun 7;18(1):130. doi: 10.1186/s13075-016-1030-1. Arthritis Res Ther. 2016. PMID: 27267896 Free PMC article.
-
Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.Arthritis Res Ther. 2017 Jun 15;19(1):141. doi: 10.1186/s13075-017-1329-6. Arthritis Res Ther. 2017. PMID: 28619044 Free PMC article.
-
Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.PLoS One. 2018 May 10;13(5):e0197219. doi: 10.1371/journal.pone.0197219. eCollection 2018. PLoS One. 2018. PMID: 29746558 Free PMC article. Clinical Trial.
-
The B cell response to citrullinated antigens in the development of rheumatoid arthritis.Nat Rev Rheumatol. 2018 Mar;14(3):157-169. doi: 10.1038/nrrheum.2018.10. Epub 2018 Feb 8. Nat Rev Rheumatol. 2018. PMID: 29416134 Review.
-
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.BioDrugs. 2025 May;39(3):373-409. doi: 10.1007/s40259-025-00708-2. Epub 2025 Mar 29. BioDrugs. 2025. PMID: 40156757 Free PMC article. Review.
References
-
- van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med. 2002;60:383–388. - PubMed
-
- Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis. 2005;64:1199–1204. doi: 10.1136/ard.2004.029389. - DOI - PMC - PubMed
-
- Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G. Induction of macrophage secretion of tumor necrosis factor α through Fcγ receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 2008;58:678–688. doi: 10.1002/art.23284. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases